Get the Stockscreener App
3.82
2.80%
-0.11
Pre-market:
3.82
Sana Biotechnology Inc stock is traded at $3.82, with a volume of 2.75M.
It is down -2.80% in the last 24 hours and down -6.14% over the past month.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
See More
Previous Close:
$3.93
Open:
$3.84
24h Volume:
2.75M
Relative Volume:
0.84
Market Cap:
$1.02B
Revenue:
-
Net Income/Loss:
$-252.18M
P/E Ratio:
-3.6038
EPS:
-1.06
Net Cash Flow:
$-185.29M
1W Performance:
-8.39%
1M Performance:
-6.14%
6M Performance:
+28.19%
1Y Performance:
+49.22%
1-Day Range:
$3.65
$4.00
1-Week Range:
$3.65
$4.29
52-Week Range:
$1.26
$6.55
Sana Biotechnology Inc Stock (SANA) Company Profile
Name
Sana Biotechnology Inc
Sector
Industry
Phone
(206) 701-7914
Address
188 EAST BLAINE STREET, SUITE 350, SEATTLE
Compare SANA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
3.82 | 1.05B | 0 | -252.18M | -185.29M | -1.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-25 | Initiated | Wedbush | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Mar-18-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Mar-14-25 | Initiated | Jefferies | Buy |
| Jan-08-25 | Upgrade | TD Cowen | Hold → Buy |
| Nov-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-26-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-25-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Aug-14-23 | Initiated | TD Cowen | Market Perform |
| May-02-23 | Initiated | H.C. Wainwright | Neutral |
| Mar-01-21 | Initiated | BofA Securities | Buy |
| Mar-01-21 | Initiated | Goldman | Neutral |
| Mar-01-21 | Initiated | JP Morgan | Neutral |
| Mar-01-21 | Initiated | Morgan Stanley | Overweight |
View All
Sana Biotechnology Inc Stock (SANA) Latest News
AI Adoption Exposes Sana Biotechnology to Rising Data, Compliance, and Reputational Risks - TipRanks
Sana Biotechnology (NASDAQ:SANA) Price Target Lowered to $7.00 at HC Wainwright - MarketBeat
Sana Biotech's Q4 Net Loss Expands; Plans To Submit IND For SC451 In 2026; Stock Down - Nasdaq
Sana Biotechnology files for mixed shelf size not disclosedSEC filing - marketscreener.com
Sana Biotechnology Files For Mixed Shelf Size Not DisclosedSEC Filing - TradingView
Sana Biotechnology (NASDAQ: SANA) files ATM to raise up to $150M with TD Cowen - Stock Titan
Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates - Bitget
Sana: Overview of Fourth Quarter Financial Results - Bitget
Sana Biotechnology Updates ATM Program to Support Development - TipRanks
Earnings Flash (SANA) Sana Biotechnology, Inc. Posts Q4 Adjusted Loss $0.16 per Share, vs. FactSet Est of $-0.14 - marketscreener.com
Going concern risk and focused pipeline at Sana Biotechnology (NASDAQ: SANA) - Stock Titan
Sana Biotechnology (NASDAQ: SANA) sets $150.0 million ATM program - Stock Titan
SANA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Sana Biotechnology, Inc. (SANA): A Bull Case Theory - Yahoo Finance
Sana Biotechnology (SANA) Stock Analysis: Exploring a Potential 104% Upside with Innovative Cell Therapies - DirectorsTalk Interviews
Sana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Sana Biotechnology (SANA) Appoints Industry Veteran Brian Piper as New CFO - Yahoo Finance
Assessing Sana Biotechnology (SANA) Valuation After The Appointment Of A New CFO - Yahoo Finance
Will Sana’s New Veteran Biopharma CFO Appointment Change Sana Biotechnology's (SANA) Investment Narrative - Sahm
Assessing Sana Biotechnology (SANA) Valuation After Recent Share Price Momentum - simplywall.st
Hear Sana Biotechnology’s March investor talks live and on replay - Stock Titan
Sana Biotechnology to Present at March 2026 Investor Conferences - Yahoo Finance
Is Sana Biotechnology Inc a stock for growth or value investorsTreasury Yields & Daily Oversold Bounce Ideas - baoquankhu1.vn
Genomics Stocks That Deserve a Place in Your Portfolio in 2026 - TradingView
Sana Biotechnology, Inc. (SANA) Stock Analysis: Unveiling a 110% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Sana Biotechnology (SANA) CFO awarded new RSUs and 900,000 options - Stock Titan
Sana Biotechnology Names Brian Piper as New CFO - The Globe and Mail
All You Need to Know About Sana (SANA) Rating Upgrade to Buy - MSN
Sana Biotechnology stock falls after naming new CFO By Investing.com - Investing.com South Africa
Sana Biotechnology, Inc. Appoints Brian Piper as Chief Financial Officer - marketscreener.com
Sana Biotechnology, Inc. Announces Executive Changes - marketscreener.com
Sana Biotechnology stock falls after naming new CFO - Investing.com
Sana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial Officer - Bitget
Sana Biotechnology (SANA) Rated ‘Market Perform’ on Diabetes Program Prospects - MSN
What’s the outlook for Sana Biotechnology Inc.’s sectorGDP Growth & Proven Capital Preservation Tips - mfd.ru
Assessing Sana Biotechnology (SANA) Valuation As Analyst Downgrade And FDA Scrutiny Weigh On Sentiment - Sahm
Is Sana Biotechnology Inc. benefiting from interest rate changesTrade Analysis Summary & Daily Entry Point Trade Alerts - mfd.ru
Sana Biotechnology: A Small, Speculative Play (NASDAQ:SANA) - Seeking Alpha
Will Sana Biotechnology Inc. benefit from geopolitical trendsFed Meeting & Reliable Volume Spike Alerts - mfd.ru
Will Sana Biotechnology Inc. benefit from sector rotationJuly 2025 Trade Ideas & AI Driven Price Predictions - mfd.ru
Flagship Pioneering Announces Appointment of Paul Parker as Managing Partner, Leading Capital Solutions - Quantisnow
Day Trade: What is the Moat Score of Sana Biotechnology IncJuly 2025 Drop Watch & Fast Entry Momentum Alerts - baoquankhu1.vn
Sana Biotechnology (NASDAQ:SANA) Downgraded by Wall Street Zen to Sell - MarketBeat
Commit To Purchase Sana Biotechnology At $2.50, Earn 26% Using Options - Nasdaq
Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health - Quantisnow
Sana Biotechnology, Inc. (SANA) Stock Analysis: 89% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Sana Biotechnology (SANA) Is Up 5.46% in One Week: What You Should Know - Yahoo Finance
Aug Levels: What are Sana Biotechnology Incs earnings expectationsEarnings Overview Summary & Daily Stock Trend Reports - baoquankhu1.vn
Is Sana Biotechnology Inc. a stock for growth or value investorsJuly 2025 Fed Impact & AI Forecast for Swing Trade Picks - mfd.ru
Sana Biotechnology, Inc. $SANA Position Boosted by Baillie Gifford & Co. - MarketBeat
Sana Biotechnology Inc Stock (SANA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sana Biotechnology Inc Stock (SANA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wyrick Susan D. | See Remarks |
Jan 02 '26 |
Option Exercise |
0.00 |
7,500 |
0 |
188,290 |
| Wyrick Susan D. | See Remarks |
Dec 13 '25 |
Option Exercise |
0.00 |
3,400 |
0 |
181,663 |
| Wyrick Susan D. | See Remarks |
Dec 03 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
180,828 |
| Wyrick Susan D. | See Remarks |
Jun 03 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
170,395 |
| Wyrick Susan D. | See Remarks |
Mar 07 '25 |
Option Exercise |
0.00 |
3,250 |
0 |
158,231 |
| Cassidy Bernard J | EVP & General Counsel |
Mar 07 '25 |
Option Exercise |
0.00 |
11,041 |
0 |
115,823 |
| Harr Steve | President & CEO |
Mar 07 '25 |
Option Exercise |
0.00 |
50,000 |
0 |
7,889,750 |
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):